Adicet Bio Inc. (NASDAQ: ACET) announced it has dosed the first patient in a Phase 1 clinical trial evaluating ADI-001 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE